← All trials
NCT06258031
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 28, 2022
- Primary completion
- Jun 28, 2024
- Completion date
- Jul 24, 2024
- First posted
- Feb 14, 2024
- Last posted
- Nov 6, 2024
- Enrollment
- 19
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Imperial College LondonLead sponsor
- Imperial College LondonOfficial
- University of HertfordshireOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.